INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
Novartis announced positive results from a phase 4 study comparing treatment with erenumab for episodic and chronic migraine.
This post hoc analysis assessed the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and QOL in adults with chronic migraine.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
The FDA has expanded the approval of Nerivio® to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine.
The FDA has accepted for review the supplemental New Drug Application (sNDA) for rimegepant for the preventive treatment of migraine.
Galcanezumab effectively treats episodic or chronic migraine after multiple standard of care preventive medication failures.
Previously, the external trigeminal nerve stimulator was only available with a prescription.
Timolol maleate ophthalmic solution was found to be effective in managing acute migraine pain.
Headache may be an early symptom of COVID-19, and identifying patients with characteristic features may help provide early isolation and treatment.